Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, multicenter study to assess the safety, tolerability,
pharmacokinetics and preliminary antitumor activity of PLB1004, and to determine the maximum
tolerated dose (MTD), dose-limiting toxicities (DLTs) and recommended phase II dose (RP2D).